Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — H1 2024 Earnings Presentation
21 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Aug 6, 2024
Slide 1: Earnings Presentation 1H 2024
Earnings Presentation 1H 2024 Jeddah | 6 August 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared solely for use as an investor presentation for Jamjoom Pharmaceuticals Factory Company (the “Company”). By attending or by reading this presentation, you agree to be bound by the following limitations. The information contained in this presentation is f
Slide 3: Business and Strategy Highlights
Business and Strategy Highlights
Slide 4: 1st Half 2024 performance highlights
4 Business and Strategy Highlights 1st Half 2024 performance highlights Revenue # of Brands +4 Consumer Health Revenue growth accelerated to 22% YoY +1 Ophthalmology 1H 24 +22% YoY driven by strong performance across key TAs 2Q 24 +9% YoY +1 General Medicine and markets SAR mn 731 139 +1 Anti-Diabet
Slide 5: Strategic growth levers for 2024
5 Business and Strategy Highlights Strategic growth levers for 2024 Home Export Portfolio Facilities Business Market Markets Diversification Ramp-up Development Initiatives • Expand in tenders • Consolidate presence • Expand consumer • Accelerate • Enhance business and grow market share health portf
Slide 6: 1st Half developments and outlook
6 Business and Strategy Highlights 1st Half developments and outlook • Overall retail market witnessed a growth of 17% (8% ex- weight-loss drugs)1 Saudi Market • JP tender sales growing at a faster pace than retail (18% vs 16%) • JP’s Wasfaty sales outpaced market growth (64% vs 37%)2 till June ‘24
Slide 7: Jeddah sterile facility fully operational whilst Egypt ramps up production
7 Business and Strategy Highlights Jeddah sterile facility fully operational whilst Egypt ramps up production SAR 100bn+ of Total Addressable Market Jeddah Jeddah Egypt Algeria in Core Geographies By 2027 Main Facility Sterile Facility Main Facility Facility Iraq Kuwait Bahrain Egypt Qatar Kingdom o
Slide 8: Accelerating revenue growth in strategic therapeutic areas and regions
8 Business and Strategy Highlights Accelerating revenue growth in strategic therapeutic areas and regions Revenue Contribution by Therapeutic Area, YoY (SARmn) Revenue Contribution by Country, YoY (SARmn) +22% +22% 11 7 731 19 731 13 5 7 20 9 16 16 30 68 43 599 599 +100% units sold c.51% local mfg.
Slide 9: Monthly revenue growth for top 5 KSA pharma in 29 months
9 Business and Strategy Highlights Monthly revenue growth for top 5 KSA pharma in 29 months 100% Peer 1 50% 11 negative months 0% -50% 200% Peer 2 100% 0% 6 negative months -100% 100% 50% 0% 1 negative month -50% 200% Peer 3 100% 10 negative months 0% -100% 100% Peer 4 50% 13 negative months 0% -50%
Slide 10: Strategic portfolio diversification to propel JP into lucrative TAs
10 Business and Strategy Highlights Strategic portfolio diversification to propel JP into lucrative TAs 2021 Revenue Contribution by Therapeutic Area (SARmn) 1H 2024 Revenue Contribution by Therapeutic Area (SARmn) Pain & Inflammation 27% C. Nervous System 5% Anti-diabetic 2% Ophthalmology Ophthalmo
Slide 11: Financial Highlights
A Layla pagans Jamjoom Pharma Financial Highlights
Slide 12: 2nd Quarter 2024 highlights
12 Financial Highlights 2nd Quarter 2024 highlights Revenue (SARmn) EBITDA (SARmn) +16% +18% 346 117 298 99 EBITDA Margin 33.1% 33.4% 33.8% 35.4% 2Q 23 2Q 24 2Q 23 2Q 24 FCF (SARmn) Net Profit (SARmn) +24% +11% 107 86 102 92 FCF conversion 93.4% 87.5% 87.4% 84.1% Net Profit Margin 28.9% 28.1% 26.7%
Slide 13: Effective OPEX management to offset rising COGS…
13 Financial Highlights Effective OPEX management to offset rising COGS… Total Cost Of Revenue Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +31% +11% 5 3 264 9 R&D/Sales decreased to 44 2.1% from 2.9% in 1H23 27 229 207 (4) (1) 202 -9% +18% -11% 1H 23 R&D Selling & Distribution Gener
Slide 14: … to preserve top-tier margins
14 Financial Highlights … to preserve top-tier margins EBITDA Movement YoY (SARmn) EBITDA and Net Profit Margins, Quarterly (%) +27% 35.4% 132 31.0% 33.8% 33.1% EBITDA Margin 26.0% 34.7% 28.9% 8 253 30.9% (62) 4 EBITDA Margin 26.3% 26.7% 33.2% (28) 199 21.4% Includes income from Algerian JV, short-t
Slide 15: Balancing cash flow efficiency with strategic business growth
15 Financial Highlights Balancing cash flow efficiency with strategic business growth Cash Conversion Cycle (Days) ▪ Cash conversion cycle expanded by a CAGR of 2.0% since 1H 2022, while revenue CAGR was 23.2%. This reflects our strategic balance of inventory +4% buildup and efficient receivables ma
Slide 16: Outlook and Guidance
A Lojla pagans Jamjoom Pharma Outlook and Guidance,» -
Slide 17: Financial guidance: Raising the bar on our 2024 targets
17 Outlook and Guidance Financial guidance: Raising the bar on our 2024 targets FY 24 Guidance 1H 2024 Actual Results FY 25-26 Guidance Revenue growth 15-18% (from 12-15%) 22.0% 12-15% EBITDA margin 31-32.5% (from 30-31.5%) 34.7% 30.0-31.5% CAPEX 4-6% 5.0% 4-6% Dividend 1H 2024 dividend of SAR 50-60
Slide 18: Q&A Session
Q&A Session Tarek Hosni, Chief Executive Officer Anwer Mohiuddin, Chief Financial Officer Muhammad Bin Khalid, Assoc. Director – Finance & IR
Slide 19: Appendix
Layla pagans Jamjoom Pharma Appendix
Slide 20: JP aims to become a significant healthcare contributor in MEA by 2026
20 Appendix JP aims to become a significant healthcare contributor in MEA by 2026 To become a leading MEA organization by 2026 through consistently providing affordable, Vision high-quality healthcare solutions Foundations Operational Excellence Strategic Execution Leadership: Positioning Track Reco
Slide 21: Pipeline overview
21 Appendix Pipeline overview R&D Status for new Products Under SFDA review Ready for SFDA Submission Under Development Total 2 Ophthalmology 5 15 8 3 General Medicine 1 5 1 Revenue growth EBITDA Dermatology margin 3 3 4 Consumer Health 7 14 3 1 Gastrointestinal 2 8 5 2 Cardiovascular 2 10 Dividend
Jamjoom Pharmaceuticals Factory — H1 2024 Earnings Presentation on 6ix